Blake Borgeson, serving as a director at Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), completed a transaction involving the sale of 40,000 shares of Class A Common Stock on July 7, 2026. The aggregate value of these shares reached $158,500. The execution of this sale occurred within a price band of $3.95 to $4.00 per share, resulting in a weighted average sale price of $3.9625. According to corporate filings, this disposition was facilitated through a Rule 10b5-1 trading plan that Borgeson originally adopted on August 31, 2025. Post-transaction, Borgeson maintains a direct holding of 6,218,287 shares of Recursion Pharmaceuticals Class A Common Stock.
The stock activity occurs against a backdrop of broader market performance and financial analysis. RXRX is currently trading at $3.76, reflecting a 33% decline over the trailing twelve months, though recent market data indicates showing strength. Independent analysis from InvestingPro suggests the stock may be undervalued at present levels, estimating a Fair Value of $4.33. The assessment notes that the company maintains a FAIR financial health score. Further insights into the company's valuation and operational metrics are available through InvestingPro's comprehensive Pro Research Report, which covers RXRX and over 1,400 other US equities.
Corporate developments extend beyond insider trading activity. Recursion Pharmaceuticals recently reported its first-quarter 2026 earnings, presenting a mixed financial picture. The company exceeded analyst expectations for earnings per share (EPS), reporting a loss of -$0.22 against a forecasted loss of -$0.26. Conversely, revenue performance fell significantly below projections, arriving at $6.47 million compared to the anticipated $16.28 million.
In parallel governance updates, shareholders approved the election of Najat Khan, Ph.D., and Franziska Michor, Ph.D., as Class II directors. Their terms will extend until the 2029 annual meeting. The voting results demonstrated substantial support, with Khan receiving 210,437,751 votes in favor and Michor receiving 208,124,737 votes in favor. Additionally, Jefferies released a report examining the potential of artificial intelligence to reduce drug development costs by up to 50%, offering context on the strategic direction of the biotech sector.
The intersection of insider transactions, financial reporting variance, and governance changes provides a snapshot of Recursion Pharmaceuticals' current operational and strategic landscape.